.jpeg)
A New Option for Advanced Renal Cell Carcinoma Treatment
Axitinib,a highly selective vascular endothelial growth factor receptor inhibitor,blocks tumor angiogenesis and suppresses tumor growth.It has proven efficacy in advanced renal cell carcinoma(RCC),offering novel treatment strategies through combination immunotherapy or monotherapy,providing hope for patients.
Indications：
1.First-Line Treatment:
●Axitinib+Avelumab:Approved for advanced RCC,synergistically enhancing antitumor response.
●Axitinib+Pembrolizumab:First-line option,significantly extending progression-free survival.
2.Second-Line Treatment:
●Monotherapy for patients who progressed after prior systemic therapy,controlling disease progression and improving survival outcomes.
Dosage and Administration：
1.Recommended Dosing:
●First-Line:Axitinib 5mg orally twice daily(12-hour interval),combined with avelumab or pembrolizumab per specified protocols.
●Second-Line:5mg twice daily,with dose adjustments based on tolerance.
2.Dose Modifications:
●Interrupt or reduce dose for severe adverse events;escalate dose if well-tolerated.
●Avoid strong CYP3A4/5 inhibitors;halve axitinib dose if co-administration is necessary.
3.Special Populations:
●No adjustment for mild hepatic impairment;reduce initial dose by half in moderate impairment.
Common Adverse Reactions：
●Hypertension,diarrhea,fatigue,hand-foot syndrome,hypothyroidism.Combination therapy may increase risks of hepatotoxicity and dysphonia;close monitoring is required.
Precautions：
1.Blood Pressure Management：Control hypertension prior to treatment;monitor regularly and adjust therapy as needed.
2.Thrombotic Events：Permanent discontinuation for arterial thrombosis;manage venous thrombosis based on severity.
3.Bleeding：Contraindicated in patients with uncontrolled active bleeding;discontinue for severe bleeding events.
4.Embryo-Fetal Toxicity：Avoid during pregnancy;recommend contraception.
5.Additional Risks：Alert for heart failure,gastrointestinal perforation,delayed wound healing,and other potential complications.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
